Xuexuan Wang1, Sam Maher, David J Brayden. 1. UCD School of Agriculture, Food Science and Veterinary Medicine, UCD Conway Institute, University College Dublin, Belfield, Dublin 4, Ireland.
Abstract
BACKGROUND: Sodium caprate (C10) is an oral absorption promoter that is currently in clinical trials as a component of solid dosage forms for poorly permeable small molecules and peptides. Clinical data with zoledronic acid tablets suggest that significant delivery along with acceptable safety can be achieved from a once-a-week dosing regime. C10 has surfactant-like properties at the high doses used in vivo and therefore we examined its effects on rat intestinal epithelium following intestinal instillation. RESULTS: Addition of 100 mM concentrations of C10 with the paracellular flux marker, fluorescein isothiocyanate-dextran 4 kDa, permitted a bioavailability of 33% to be achieved. When C10 was added 10, 30 and 60 min in advance of fluorescein isothiocyanate-dextran 4 kDa, enhancement still occurred, but was progressively reduced. Histology revealed that the permeability increase was likely related in part to superficial epithelial damage caused in the first few minutes of exposure, which was rapidly repaired within 30-60 min. CONCLUSIONS: Design of optimized dosage forms containing C10 should corelease the payload and promoter close to the epithelium in high concentrations. While C10 induces some epithelial damage, its remarkable capacity for epithelial repair may render this effect insignificant in vivo.
BACKGROUND:Sodium caprate (C10) is an oral absorption promoter that is currently in clinical trials as a component of solid dosage forms for poorly permeable small molecules and peptides. Clinical data with zoledronic acid tablets suggest that significant delivery along with acceptable safety can be achieved from a once-a-week dosing regime. C10 has surfactant-like properties at the high doses used in vivo and therefore we examined its effects on rat intestinal epithelium following intestinal instillation. RESULTS: Addition of 100 mM concentrations of C10 with the paracellular flux marker, fluorescein isothiocyanate-dextran 4 kDa, permitted a bioavailability of 33% to be achieved. When C10 was added 10, 30 and 60 min in advance of fluorescein isothiocyanate-dextran 4 kDa, enhancement still occurred, but was progressively reduced. Histology revealed that the permeability increase was likely related in part to superficial epithelial damage caused in the first few minutes of exposure, which was rapidly repaired within 30-60 min. CONCLUSIONS: Design of optimized dosage forms containing C10 should corelease the payload and promoter close to the epithelium in high concentrations. While C10 induces some epithelial damage, its remarkable capacity for epithelial repair may render this effect insignificant in vivo.
Authors: Staffan Berg; Denny Suljovic; Lillevi Kärrberg; Maria Englund; Heiko Bönisch; Ida Karlberg; Natalie Van Zuydam; Bertil Abrahamsson; Andreas Martin Hugerth; Nigel Davies; Christel A S Bergström Journal: Mol Pharm Date: 2022-06-01 Impact factor: 5.364
Authors: Staffan Berg; Lillevi Kärrberg; Denny Suljovic; Frank Seeliger; Magnus Söderberg; Marta Perez-Alcazar; Natalie Van Zuydam; Bertil Abrahamsson; Andreas M Hugerth; Nigel Davies; Christel A S Bergström Journal: Mol Pharm Date: 2021-12-20 Impact factor: 4.939
Authors: Shakhawath Hossain; Paul Joyce; Albin Parrow; Silver Jõemetsa; Fredrik Höök; Per Larsson; Christel A S Bergström Journal: Mol Pharm Date: 2020-10-08 Impact factor: 4.939
Authors: Joanne Heade; Fiona McCartney; Miguel Chenlo; Olga Moreno Marro; Maja Severic; Robert Kent; Sinead B Bleiel; Clara V Alvarez; Brendan T Griffin; David J Brayden Journal: Pharmaceutics Date: 2021-05-04 Impact factor: 6.321